Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Evolus, Inc. - Common Stock
(NQ:
EOLS
)
7.470
UNCHANGED
Delayed Quote
Updated: 4:00 PM EST, Nov 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Evolus, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
November 03, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Evolus to Participate in Upcoming Investor Conferences in New York and London
October 28, 2026
From
Evolus
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
October 27, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Evolus to Report Third Quarter Financial Results on November 4, 2026
October 21, 2026
From
Evolus
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
October 20, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
October 14, 2026
From
Evolus, Inc.
Via
Business Wire
EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law
October 12, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
October 06, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes
October 01, 2026
From
Evolus
Via
Business Wire
Telix Appoints David Gill as Chair
August 31, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
August 05, 2026
From
Evolus
Via
Business Wire
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
August 04, 2026
From
Evolus
Via
Business Wire
Evolus to Report Second Quarter Financial Results on August 5, 2026
July 22, 2026
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
From
Evolus
Via
Business Wire
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
July 08, 2026
From
Evolus
Via
Business Wire
Evolus to Participate in The Jefferies Global Healthcare Conference
May 19, 2026
From
Evolus
Via
Business Wire
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
May 11, 2026
From
Evolus
Via
Business Wire
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
May 04, 2026
From
Evolus
Via
Business Wire
Evolus to Report First Quarter Financial Results on May 4, 2026
April 14, 2026
From
Evolus
Via
Business Wire
Telix Appoints David Gill as Non-Executive Director
April 01, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
March 31, 2026
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 20, 2026
From
Evolus
Via
Business Wire
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026
March 03, 2026
From
Evolus
Via
Business Wire
Evolus to Participate in The Leerink Partners Global Healthcare Conference
February 25, 2026
From
Evolus
Via
Business Wire
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
February 17, 2026
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2026
From
Evolus
Via
Business Wire
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
January 09, 2026
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 14, 2025
From
Evolus
Via
Business Wire
Evolus Reports Third Quarter 2025 Financial Results
November 05, 2025
From
Evolus
Via
Business Wire
Evolus to Participate in 2025 Stifel Healthcare Conference
October 28, 2025
From
Evolus
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
